ADMA Biologics Inc (ADMA) support and resistance · P/E 22, rev $426.5M
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
This page maps ADMA Biologics Inc (ADMA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ADMA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ADMA quote page for the session range and the stock page for the full model.
Not investment advice.